{
    "2021-10-22": [
        [
            {
                "time": "",
                "original_text": "金斯瑞蓬勃生物牵手艾博生物、沃森生物 加速新冠疫苗商业化进程",
                "features": {
                    "keywords": [
                        "金斯瑞蓬勃生物",
                        "艾博生物",
                        "沃森生物",
                        "新冠疫苗",
                        "商业化"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "国泰君安：新冠疫苗进入业绩兑现期，港股部分标的将受益",
                "features": {
                    "keywords": [
                        "国泰君安",
                        "新冠疫苗",
                        "业绩兑现",
                        "港股"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "港股市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}